Radomski, Shannon N.
Greer, Jonathan B.
Johnston, Fabian M.
Ewald, Andrew J.
Funding for this research was provided by:
Johns Hopkins SPORE in Gastrointestinal Cancer
Giovanis Institute for Translational Cell Biology
Black in Cancer/Emerald Foundation
National Cancer Institute (5T32CA126607, T32CA153952, U54CA268083)
American College of Surgeons (Resident Research Scholarship)
Commonwealth Foundation for Cancer Research Foundation
Article History
Received: 4 December 2023
Accepted: 7 December 2023
First Online: 19 January 2024
Disclosure
: The authors received support from the NIH/NCI 5T32CA126607 (S.N.R.), NIH/NCI U54CA268083 (A.J.E.), the American College of Surgeons Resident Research Scholarship (S.N.R.), the Commonwealth Foundation for Cancer Research (F.M.J., A.J.E.), the Johns Hopkins SPORE in Gastrointestinal Cancer at the Sidney Kimmel Comprehensive Cancer Center (S.N.R., A.J.E.), the Giovanis Institute for Translational Cell Biology (A.J.E.). Andrew J. Ewald has unlicensed patents related to keratin 14 as a prognostic marker and to antibody strategies for anti-cancer therapeutics. He is a consultant for BioNTech, and his spouse is an employee of ImmunoCore. The remaining authors have no conflicts of interest.